PDCD1 and neoplasm: In addition, a 63-year-old male patient with nasal AS that received pembrolizumab 2 mg/kg every 21 days for 13 cycles had no new tumor progression during the 8 months after therapy, which suggested that PD-1/PD-L1 immune checkpoint inhibitors have significant efficacy against angiosarcomas (117).